Perspectives on weight control in diabetes – Tirzepatide

• Published in: Diabetes research and clinical practice 2023-08, Vol.202, p.110770-110770, Article 110770
• Main Authors: Várkonyi, Tamás T., Pósa, Anikó, Pávó, Noémi, Pavo, Imre
• Format: Article
• Language: English
• Subjects: Body weight; Cardiovascular diseases; Diabetes; Obesity; Weight loss
• ISSN: 0168-8227; 1872-8227
• DOI: 10.1016/j.diabres.2023.110770

Tirzepatide, a once-weekly glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist (GIP/GLP-1 RA) improves glycemic control. Besides improvement of glycemic control, tirzepatide treatment is associated with significantly more weight loss as compared to potent selective GLP-1 receptor agonists as well as other beneficial changes in cardio-metabolic parameters, such as reduced fat mass, blood pressure, improved insulin sensitivity, lipoprotein concentrations, and circulating metabolic profile in individuals with type 2 diabetes (T2D). Some of these changes are partially associated with weight reduction. We review here the putative mechanisms of GIP receptor agonism contributing to GLP-1 receptor agonism-induced weight loss and respective findings with GIP/GLP-1 RAs, including tirzepatide in T2D preclinical models and clinical studies. Subsequently, we summarize the clinical data on weight loss and related non-glycemic metabolic changes of tirzepatide in T2D. These findings suggest that the robust weight loss and associated changes are important contributors to the clinical profile of tirzepatide for the treatment of T2D diabetes and serve as the basis for further investigations including clinical outcomes.